Regarding the same topic PSMA/FDG, the Australian and New Zealand Urogenital and Prostate Cancer Trial Group prospectively collected the quantitative parameters of both pre-treatment PET in the TheraP cohort (Lu-PSMA-617 vs. cabazitaxel), measuring MTV, SUVmax, and SUVmean. This evidence concerns the gene FOLH1 and prostate cancer.